Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis.

33 , 34 A β coefficient of 0.32 is defined as significant, 0.45 as substantially significant and 0.60 as highly significant (0.60 considered clinically meaningful). 32 Results Of 90 studies identified initially, 19 were eligible (patients included from September 1996 to March 2018), including 4 prospective and 15 retrospective studies ( Figure 1 ). 8 – 25 , 35 There were no published results from second-line randomised studies in advanced EP-PD-NEC reported in the literature.

also in 132,142 other papers